1-4 of 4
Liyu Zhou
Close
Sort by
Journal Articles

DNMT3A wt NPM1-Mutation Defines a Subgroup of MDS with Special Favorable Outcomes Towards Decitabine Therapy

Lingyun Wu, MD PhD, Xiao Li, MD, Feng Xu, He Qi, Zheng Zhang, Dong Wu, Luxi Song, MD, Liyu Zhou, Chao Xiao, Jiying Su, Juan Guo, Chunkang Chang
Journal: Blood
Blood (2019) 134 (Supplement_1): 1724.
https://doi.org/10.1182/blood-2019-124008
Published: 2019
Journal Articles

Cytogenetic Response Based On Revised IPSS Cytogenetic Risk Stratification and Minimal Residual Disease Monitoringby FISH In MDS Patients Treated By Low-Dose Decitabine

Xiao Li, MD, PhD, Chunkang Chang, Qi He, Feng Xu, Qingxia Zhang, Lingyun Wu, Jiying Su, Xi Zhang, Liyu Zhou, Dong Wu, Zheng Zhang
Journal: Blood
Blood (2013) 122 (21): 1575.
https://doi.org/10.1182/blood.V122.21.1575.1575
Published: 2013
Journal Articles

Efficacy and Toxicity Of Decitabine Versus CHG Priming Regimen In Patients With Higher Risk Myelodysplastic Syndrome

Lingyun Wu, Xiao Li, MD, PhD, Feng Xu, Chunkang Chang, Qi He, Zheng Zhang, Luxi Song, Xi Zhang, Jiying Su, Liyu Zhou
Journal: Blood
Blood (2013) 122 (21): 2789.
https://doi.org/10.1182/blood.V122.21.2789.2789
Published: 2013
Journal Articles

The Incidence of Corrected Hypercalcemia and Its Relationship with Prognosis for Chinese Multiply Myeloma.

Xi Zhang, Chunkang Chang, Xiao Li, MD, PhD, Jiying Su, Lingyun Wu, MD, Liyu Zhou, Qi He, Li Xu, Luxi Song, Quan Pu
Journal: Blood
Blood (2009) 114 (22): 4903.
https://doi.org/10.1182/blood.V114.22.4903.4903
Published: 2009